A Nomogram for Drug Dosage in Renal Failure,Based on Mean Plasma Concentrations

Abstract

Get full access to this article

View all access options for this article.

References

Wagner

J.G.

.: Blood levels of drug at the equilibrium state after multiple dosing. Nature 207: 1301–1302, 1965.

Rowland

, Tozer

T.T.

: Clinical pharmacokinetics: concepts and applications. Lea & Febiger, Philadelphia, 1980.

Goodman & Gilman, Pharmacological Basis of Therapeutics. 6th Edition, 1980. Macmillan, New York. Eds, Goodman-Gilman

Alfred

, Goodman

Louis F.

, Gilman

Alfred

Zaske

D.E.

, Cipolle

R.J.

, Strate

R.J.

: Gentamicin dosage requirements wide interpatient variations in 242 surgery patients with normal renal function. Surgery 87: 2: 164–169, 1980.

Zaske

D.E.

, Cipolle

R.J.

, Strate

R.G.

, Dickes

W.F.

: Increased gentamicin dosage requirements: rapid elimination in 249 gynecology patients. Am. J. Obstet Gynecol. 139: 8: 896–900, 1981.

Schentag

J.J.

: Aminoglycoside tissue accumulation: a comparison between gentamicin and tobramycin. Symposium: Assessment of Aminoglycoside Toxicity, Burgenstock, Switzerland, September 24–25, 1977, p. 26–31.

Ash

S.R.

, Millikan

M.D.

: Optimizing tobramycin therapy in a hemodialysis patient. Inter. J. Artif. Organs 5: 4: 279–280, 1982.

Sketris

I.S.

, Skoutakis

V.A.

: Dialysis and hemoperfusion of drugs and toxins. Clin. Toxicol. Consult. 3: 100–117, 1981.

Jusko

W.J.

, Lewis

G.P.

, Schmitt

G.W.

: Ampicillen and hetacillen pharmacokinetics in normal and anephric subjects. Clin. Pharmacol. Therap. 14: 90–98, 1973.

10.

Aronoff

G.A.

.: Moxalactam pharmacokinetics during hemodialysis. Antimicrob. Agent Chemoter. 19: 575–577, 1981.

11.

Nattel

.: Procainamide acetylation and disposition in dialysis patients. Clin Invest. Med. 2: 5–11, 1979.

12.

Gibson

T.P.

, Matusik

, Briggs

W.A.

: N-acetyl procainamide levels in patients with end-stage renal failure. Clin. Pharmacol. Ther. 19: 206–212, 1976.

13.

Stec

G.P.

.: N-acetyl procainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin. Pharmacol. Ther. 26: 618–628, 1979.

14.

Latos

D.L.

, Bryan

C.S.

, Stone

W.J.

: Carbenicillen therapy in patients with normal and impaired renal function. Clin. Pharmacol. 17: 692–700, 1975.

15.

Pizzella

K.M.

.: Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. Ther drug Monitoring 2: 273–281, 1980.

16.

Herrera

, Vukovich

R.A.

, Griffith

D.L.

: Elimination of nadolol by patients with renal impairment. Br. J. Clin. Pharmacol. 7: 227–231Suppl. 2, 1979.

17.

Gibson

T.P.

.: Elimination of procainamide in end-stage renal failure. Clin. Pharmacol. Ther. 17: 321–329, 1975.

18.

Kampf

.: Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrob. Agents Chemoter. 18: 81–87, 1980.

19.

Chodos

.; pharmacokinetics of intravenous cefotoxime in patients undergoing hemodialysis. Ther Drug Monitoring 3: 71–74, 1981.

20.

Whelton

.: Pharmacokinetics of doxycycline in the absence of renal function. Kidney Int.: 5: 365–371, 1974.

21.

Blouin

R.A.

.: Chloramphenicol hemodialysis clearance. Ther Drug Monitoring 2: 351–354, 1980.

22.

Jacobi

.: Hemodialysis clearance of total and unbound lidocaine. Clin. Pharmacy 2: 54–57, 1983.

23.

Vaziri

N.D.

, Saiki

J.K.

, Hughes

: Clearance of lidocaine by hemodialysis. So. Med. J. 72: 1567–1568, 1979.

24.

Lowenthal

D.T.

.Pharmacokinetics of oral propanolol in chronic renal disease. Clin. Pharmacol. Ther. 16: 761–769, 1974.

25.

Adir

.: Pharmacokinetics of bretylium in renal insufficiency. NEJM 300: 1390–1391, 1979.

26.

Gibson

T.P.

, Nelson

H.A.

: Drug kinetics and artificial kidneys. Clin. Pharmacokinetics 2: 403–426, 1977.

27.

Kreeft

j.H.

.: Metronidazole kinetics in dialysis patients. Surgery 93: 149–153, 1983.